Ceva Animal Health has agreed to acquire IDT Biologika’s veterinary division, a manufacturer of swine, cattle and poultry vaccines.
The deal between France-based Ceva and privately owned IDT is subject to regulatory approval and is expected to close by July 1. The terms were not disclosed.
“IDT has significant expertise in a number of other areas, including autogenous vaccines and oral vaccination for the control of endemic disease in wildlife and free-roaming animals, adding important new technology, especially in rabies control, to Ceva’s growing public health business,” the companies noted in a joint statement.
IDT will keep its human medicine business, which accounts for two-thirds of the company’s revenue and focuses on the development of drugs and vaccines. IDT is based in Dessau-Rosslau, Germany.
“We will continue to manufacture the divested animal health products for Ceva for at least five years at our Dessau site,” said Carsten Klocke, CEO of parent company Klocke Holding Group. “This transaction and the clear focus will allow IDT to grow even faster and at the same time mutually support the One Health Initiative — IDT in human and our partner, Ceva, in animal health.”
Ceva’s U.S. operations are headquartered in Lenexa, Kansas. Among the company’s products are Vectra, Feliway and MilbeGuard for companions animals, swine vaccines and an iron supplement for piglets.